Key points are not available for this paper at this time.
Modern immunotherapies are reshaping the treatment landscape of multiple myeloma (MM), offering the possibility of deeper responses and prolonged survival.Over the past five years, chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies (BsAb), and antibody-drug conjugates (ADCs) have been developed and approved, first in the relapsed/refractory MM (R/RMM) setting and progressively in earlier lines of therapy, underscoring a shift toward their use across the entire disease course, including at diagnosis.Concurrently, novel therapeutic constructs, such as trispecific antibodies, dualtarget CAR T-cells, and combinations of different T-cell-redirecting therapies or their integration with standard agents are currently under investigation across the entire treatment landscape.Despite their remarkable efficacy, these therapies are associated with distinct and clinically relevant toxicities that require careful understanding and management.These include well-recognized adverse events associated with CAR T-cell therapies and BsAb, such as cytokine release syndrome and immune effector cellassociated neurotoxicity syndrome, as well as an increased risk of infections, additional neurologic complications, and the ocular toxicity observed with belantamab mafodotin.In this review, we discuss the efficacy and safety profiles of CAR T-cell therapies, BsAb and belantamab mafodotin within the current MM treatment landscape, highlighting evidence from both clinical trials and real-world studies, and providing an overview of available data on therapeutic sequencing strategies. Immunotherapy in relapsed-refractory multiple myeloma: late linesBelantamab mafodotin and TCR therapies were initially approved as monotherapies for triple class (IMiDs, PIs and anti-CD38 mAbs) exposed patients.Belantamab mafodotin received conditional Food and Drug Administration (FDA) approval after the DREAMM-2 trial 9 for use after at least four prior lines of therapy.However, it was subsequently withdrawn from the market as the DREAMM-3 study failed to demonstrate a statistically
Cani et al. (Sat,) studied this question.